复星医药最新公告：斯鲁利单抗注射液新适应症获国家药监局批准

证券之星06-09 18:10

复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增适应症获国家药监局批准，本次获批适应症为联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗。该药品为全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，有助于增强市场竞争力。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2642469217?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-09 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642469217","market":"fut","top_or_hot":-1,"title":"复星医药最新公告：斯鲁利单抗注射液新适应症获国家药监局批准","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600196\">复星医药</a>(600196.SH)公告称，公司控股子公司<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>自主研发的斯鲁利单抗注射液新增适应症获国家药监局批准，本次获批适应症为联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗。该药品为全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，有助于增强市场竞争力。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/15936120260609.png\"/><img src=\"https://static.stockstar.com/etf/58808020260609.png\"/><img src=\"https://static.stockstar.com/etf/51201020260609.png\"/><img src=\"https://static.stockstar.com/etf/51608020260609.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药最新公告：斯鲁利单抗注射液新适应症获国家药监局批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药最新公告：斯鲁利单抗注射液新适应症获国家药监局批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-09 18:10 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026060900029768.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增适应症获国家药监局批准，本次获批适应症为联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗。该药品为全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，有助于增强市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF</p>\n\n<a href=\"https://stock.stockstar.com/RB2026060900029768.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"https://stock.stockstar.com/RB2026060900029768.shtml","article_id":"2642469217","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642469217","pubTimestamp":1780999822,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增适应症获国家药监局批准，本次获批适应症为联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗。该药品为全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，有助于增强市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK0060":"抗癌","BK1593":"医美概念股","BK0028":"国家队","02196":"复星医药","BK0096":"民营医院","BK0239":"医药制造","BK1191":"制药","BK0183":"MSCI概念","BK0188":"融资融券","BK1515":"抗疫概念","BK0012":"证金概念"},"translate_title":"Fosun Pharma's latest announcement: The new indication of Slulumab injection was approved by the National Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增适应症获国家药监局批准，本次获批适应症为联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗。该药品为全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，有助于增强市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642469217","isCrawlerRequest":true}